Prot #ACP-103-038: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia

Project: Research project

Project Details

StatusFinished
Effective start/end date3/15/17 → 6/30/22

Funding

  • Quintiles, Inc. ((OE) Prot #ACP-103-038 // (OE) Prot #ACP-103-038)
  • ACADIA Pharmaceuticals Inc. ((OE) Prot #ACP-103-038 // (OE) Prot #ACP-103-038)